In this monologue, the presenter uses the hammer‑vs‑jar metaphor to argue that statins, the world’s most profitable cholesterol‑lowering drugs, are a tool that must be matched to the right patient. He reviews a newly released observational coronary CT angiography (CTA) study of 11,026 patients (median 3.3‑year follow‑up) which found a 20% relative risk reduction in major adverse cardiovascular events only among those with obstructive coronary disease, while showing no benefit in patients with minimal or no disease on imaging. The speaker places these findings in the context of earlier work showing that zero coronary artery calcium (CAC) scores nullify risk even in people with very high LDL, underscoring that imaging provides superior risk stratification to lipid biomarkers alone. He then outlines the mechanistic pros of statins (LDL/ApoB reduction, anti‑inflammatory, vasodilation) and the cons (mitochondrial dysfunction via CoQ loss, muscle impairment, gut‑microbiome disruption, GLP‑1 suppression, increased diabetes risk). The discussion shifts to the economic incentives that push pharmaceutical companies to broaden statin indications, and to clinician psychology—particularly on social media—where fear of undermining established narratives can lead to dismissive or dogmatic messaging that erodes patient trust. The presenter advocates a collaborative, shared‑decision‑making model that presents pros, cons, and alternatives (ezetimibe, bempedoic acid, lifestyle changes) rather than blanket prescribing. He concludes that statins are valuable for patients with documented coronary disease but are not universally beneficial, urging transparency, humility, and nuanced conversation to preserve trust and improve care.
Chapters
A hammer's a great tool if you want to drive a nail into a wall. But it's a terrible tool if you want to open a jar of pickles. The point is obvious, and you shouldn't need a medical degree to figure it out. The tool should fit the job. That's as true for hammers as it is for medications. And today, we're talking about one of the most profitable and controversial tools in medicine: statin drugs for lowering cholesterol. And that's because a new paper just dropped, yesterday as I record this, and the opinions on it could not be more split. Some are already saying this proves we're overprescribing statins, whereas others are calling it irresponsible noise. So what's actually true? Should you be worried? Well, let's unpack not one, but four major studies, some history, and then the real risks and benefits behind One of the world's most common medications and most misunderstood medications. If you stick around, I promise you're going to learn more in the next few minutes about the world's most profitable drug than they teach in 4 years of medical school. You can trust me on that. Let's go. This could occur even without symptoms. Zero. Zilch. I was caught off guard by this. Statins smash GLP-1 levels into the floor, increasing the risk of type 2 diabetes. It's almost malpractice. Drug companies are not in the business of shrinking their customer base. Because if you're selling hammers, you want everything to look like a nail. That's not a conspiracy theory. That's just basic logic and economics. It erodes trust. The effects are complex and mixed. Clinging too tightly to the status quo doesn't prevent rebellion. It fuels it. First, let's get at this most recent study. This paper set out to evaluate whether statins reduce major adverse cardiovascular events, such as heart attacks or death, in patients with varying degrees of cardiovascular disease, as measured with imaging called CT angiography, or CTA. The bottom line, simply put: statins were associated with a reduced risk of major adverse cardiovascular events in those, specifically in those, who had pre-existing heart disease, but showed no benefit in those without cardiovascular disease on imaging. So let's get into a little bit more detail. The study included 11,026 patients, average age 59, roughly half men and half women. These patients underwent coronary CT angiography scans to look for plaque in their arteries, and then were followed for a median time period of 3.3 years. As a taste of the data, in patients with severe obstructive coronary disease, so like half or more of a vessel is blocked, statins were protective with a 20% relative risk reduction—that is relative—but risk reduction in patients with this pre-existing advanced disease. However, in patients with minimal or no disease, statins showed no benefits for cardiovascular outcomes. Zero. Zilch. So the punchline is quite simple: statins reduced risk in patients with established and advanced cardiovascular disease, but in patients with no cardiovascular disease on imaging, like a coronary CT angiography scan or a CAC scan, there was no benefit. But this study isn't the be-all end-all. In fact, as far as studies go, it wasn't that strong, nor novel in many respects. It was an observational study, not a controlled trial. They didn't look at associations with cholesterol levels, or different statins, or different doses. So why am I making a thing about this at all? Well, first of all, because the internet's making a thing. But here's the real twist: these findings aren't at all novel, but they're consistent with prior literature and reflect a trend in the field. Cardiovascular imaging provides better risk stratification than relying on biomarkers alone like LDL cholesterol or ApoB. I know we talk about them a lot, but this kind of makes sense, doesn't it? It's just common sense. In a comparison between measuring disease and looking at one biomarker for disease, which isn't necessarily even a strong biomarker—LDL or ApoB—are we surprised that measuring the disease with imaging wins? It's like checking your weather app and then stepping outside into a thunderstorm. Yeah, it turns out being in the storm tells you more than the forecast. But let me provide another example from the literature. In a more famous prior trial, They found that patients with elevated LDL, very high LDL above 190 mg/dL, actually had similar cardiovascular risk to those with very low LDL when their coronary artery calcium scores, their cardiac scans, were zero, when clean. So even after nearly a decade of elevated LDL cholesterol exposure, it didn't raise risk when imaging was clean. And again, this makes physiologic sense because LDL and ApoB are just small pieces of a larger puzzle. They may not represent big slices of the risk pie, but they do dominate our attention. Why? Because we have drugs to treat them. We'll get to more on that later. But meanwhile, heavier risk factors like insulin resistance, they require interventions that are more difficult to implement and less profitable from a business perspective. Think diet, exercise, and other lifestyle changes. There's not a simple pill. There's no easy billing code. So these don't get as much focus. But I'm not done with you yet, not even close, because this topic deserves much more critical thought and deeper consideration. So first, let's review at a high level some of the mechanistic pros and cons of statins. I'm going to try to give an even hand here. On the potential benefits side, the most well-known effect of statins is their ability to lower LDL cholesterol and ApoB. They do this by inhibiting cholesterol synthesis, an enzyme called HMG-CoA reductase. And as a result, the liver upregulates LDL receptors to compensate, and it pulls LDL particles out of circulation. This is how statins work. And in people with cardiovascular risk, this can reduce events, as the data we reviewed showed. LDL particles are part of the causal chain of heart disease atherosclerosis. Whether or not they're sufficient to cause heart disease, and I argue they aren't, Still, removing something from a causal chain can reduce risk. That shouldn't be controversial. But there are downsides. For example, statins inhibit cholesterol synthesis in other tissues along with downstream products of that pathway—things like coenzyme Q, which are important for mitochondrial function—and statins can negatively impact mitochondrial function. As a case in point, another human trial that we covered earlier on this channel found that even at very low concentrations in the human body, the most common statin, atorvastatin, can block the function of complex IV in the mitochondrial electron transport chain in association with impairments in muscle performance and recovery. And of note, this could occur even without symptoms. So that raises the genuine question, the fair question: What could be the long-term negative consequences of mitochondrial harm caused by statins especially for healthy people. Now, continuing this game of pro-con tennis, statins also reduce inflammation and promote vasodilation, the opening of blood vessels, which can be helpful in those with high baseline inflammation, especially people who are metabolically unhealthy. But back to the cons. Statins can also alter the gut microbiome, disrupt it, reduce levels of key bile acids, suppress GLP-1, and promote insulin resistance, increasing the risk of type 2 diabetes. The impact of statins on increasing diabetes risk isn't actually new news. It's old news. But what was new news to me was a human-controlled trial published in one of my favorite journals last year showing that astonishingly, statins smash GLP-1 levels into the floor. I want to make sure that tennis ball didn't hit anything important. Statins smash GLP-1 levels into the floor. And I was caught off guard by this because how is it that a major journal publishes a controlled human trial showing that the world's most profitable medication in lowers levels of a key metabolic health hormone that itself is the target of the most trendy drug class of the modern era, GLP-1 weight loss drugs, and not only does it not make headline news, but doctors don't have this information in their brains to share with patients. It's almost malpractice. And if you want more on that study, you can see this video. But the biochemistry of statins is not the point. The point is the effects are complex and mixed. And to assess that balance in each individual patient is part of the art of medicine. And to conclude that in those without cardiovascular disease as assessed by imaging, the harms of statins outweigh the benefits, it's not only reasonable, it's the responsible thing to do. Because there are downsides. But I'm still not done with you. Because beyond biology, we need to talk about human psychology and social dynamics, especially the economic and structural forces that shape how statins are prescribed, and how we talk about them. So let's start with the business model. Drug companies— this is an obvious fact, but drug companies are not in the business of shrinking their customer base. It's more profitable to maintain a broad, loosely defined population who qualify for treatment. So if you study a metabolically unhealthy group, basically our United States population, finding even a tiny statistically significant effect in the whole population allows you to justify prescribing the drug to everyone in that group. But if you break it down further, you may find only a subset benefit and they're driving the effect while others have no benefit or even harmed. If you did this though, the customer pool shrinks and your profits go down. So from a business perspective, the question isn't how much can we help people, it's can we prescribe this drug to this person and the most people. That's not a conspiracy theory, that's just basic logic in economics. Because if you're selling hammers, you want everything to look like a nail. And then there's clinician psychology, particularly among clinicians and physicians who are active on social media. This is my take: I think clinicians get anxious when data challenge a prevailing narrative around statins. The fear is if the science gives an inch, then the twisted megaphone of social media will take 10 miles, and patients will start refusing medications that could help them, leading to avoidable harm. And in general, I believe their concern is rooted in deep care for their patients, wanting to help their patients. But the result often comes across as arrogance, dismissiveness, and even academic elitism, and this leads to the opposite of the intended effect. It erodes trust. People dig in deeper and they double down on the alternative view. In essence, clinging too tightly to the status quo doesn't prevent rebellion, it fuels it. So what will be better? How about a calm, transparent, collaborative approach? Imagine your doctor saying to you, so here are the pros and cons of this medication. Here are the other options for you, like lifestyle changes or other medications. Let's talk about ezetimibe or bempedoic acid. "Let's decide on this together. Tell me what your priorities are, what your concerns are. Let's have a discussion. I'm not the all-knowing cardiovascular authority. I, as your doctor, I'm your consultant and your partner. Let's have a chat." How would that go? And to be fair, I think many physicians actually do this well in the clinic, but this approach doesn't translate to the social media sphere. So let's wrap this all up. In conclusion, again, the right tool for the right job. Statins are a tool, potentially valuable in the right context, but not universally beneficial. This isn't about throwing out statins or embracing conspiracy. It's not black or white. It's about nuance over dogma and recognizing that effective medicine, good medicine, means matching the intervention to the right patient in the right context. But to do that well, We need transparency in research. We need honesty about limitations and humility about our public messaging. Otherwise, we risk eroding trust and widening the very gap we're trying to close. The answer isn't more noise. It's better conversation. And that starts with acknowledging the complexity and partnering with patients, not preaching to them. Stay curious and let me know if this was valuable to you.
